| Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin-paclitaxel chemotherapy. | |
| | |
MedLine Citation:
|
PMID: 16051334 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: We evaluated the characteristics and determinants of 5-year survival in ovarian cancer patients with complete response after first line treatment who entered a randomised study comparing two different chemotherapeutic schedules. METHODS: This analysis included 232 ovarian cancer patients with complete response after first line surgery and chemotherapy coming from a large randomised trial comparing the effect of different doses of paclitaxel combined with fixed doses of carboplatin. RESULTS: The 5-year overall survival in patients was 57.3%. The difference in 5-year survival for age <52 years (65.1%), 53-62 (51.4%) and > or = 63 (51.2%) was statistically significant (P = 0.048). The 5-year overall survival rates were 64.6% for stage III and 57.9% for stage IV. Serous and clear cell histotypes had a worse 5-year overall survival (51.5% and 50.8% respectively), while the endometrioid and mucinous had 67.1% and 71.4%: these differences were statistically different (P = 0.04). Women with residual tumour of 1 cm or smaller after primary surgery had better 5-year survival rates: 71.2% for patients with residual tumour < or = 1 cm and 46.9% for residual tumour >1 cm: these differences were statistically significant (P < 0.006). CONCLUSION: This study shows that in women with ovarian cancer and complete response after first line surgery and chemotherapy, age, histotype and residual tumour after surgery are determinants of 5-year overall survival. |
| | |
Authors:
|
Gianpiero Polverino; Fabio Parazzini; Giovanna Stellato; Giovanna Scarfone; Sonia Cipriani; Giorgio Bolis |
Related Documents
:
|
16445624 - Malignant transformation of ovarian mature cystic teratoma. 23055534 - 11c-methionine pet for grading and prognostication in gliomas: a comparison study with ... 8823334 - Phase ii study of vinorelbine in patients with pretreated advanced ovarian cancer: acti... 11578404 - Long-term survival and prognostic factors in advanced epithelial ovarian cancer with sp... 21516504 - Transoral co(2) laser management for selected supraglottic tumors and neck dissection. 23278394 - Treatment of estrogen receptor-positive breast cancer. |
Publication Detail:
|
Type: Journal Article; Randomized Controlled Trial Date: 2005-07-26 |
Journal Detail:
|
Title: Gynecologic oncology Volume: 99 ISSN: 0090-8258 ISO Abbreviation: Gynecol. Oncol. Publication Date: 2005 Nov |
Date Detail:
|
Created Date: 2005-10-24 Completed Date: 2005-12-01 Revised Date: 2006-04-24 |
Medline Journal Info:
|
Nlm Unique ID: 0365304 Medline TA: Gynecol Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 343-7 Citation Subset: IM |
Affiliation:
|
Prima Clinica Ostetrico Ginecologica, Università di Milano, via Commenda 12, 20122 Milano, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antineoplastic Combined Chemotherapy Protocols
/
therapeutic use* Carboplatin / administration & dosage Chemotherapy, Adjuvant Drug Administration Schedule Female Humans Middle Aged Ovarian Neoplasms / drug therapy*, surgery Paclitaxel / administration & dosage Prognosis Survival Rate Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
33069-62-4/Paclitaxel; 41575-94-4/Carboplatin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: CD10, estrogen and progesterone receptor expression in ovarian adenosarcoma.
Next Document: Erythropoietin receptor function and expression in epithelial ovarian carcinoma.